Velmanase Alfa
Velmanase alfa is a recombinant human lysosomal alpha-mannosidase produced in Chinese hamster ovary cells for enzyme replacement therapy (ERT) in patients with alpha-mannosidosis, a rare lysosomal storage disease caused by deficiency of the alpha-mannosidase enzyme. It catalyzes the hydrolysis of mannose-containing oligosaccharides in lysosomes, preventing their pathological accumulation in cells. Regular intravenous infusions reduce mannose-rich oligosaccharide levels and improve clinical manifestations of the disease.
Molecular Weight
65.4000 g/mol
TPSA
0.00 Ų
Mechanism of Action
As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.
SMILES
[Zn+2]
InChI
InChI=1S/Zn/q+2
Molecular Formula
Zn+2
HBD / HBA
- / -
Rotatable Bonds
0
Heavy Atoms
1
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Frequently Asked Questions
Velmanase alfa is a recombinant human lysosomal alpha-mannosidase produced in Chinese hamster ovary cells for enzyme replacement therapy (ERT) in patients with alpha-mannosidosis, a rare lysosomal storage disease caused by deficiency of the alpha-mannosidase enzyme. It catalyzes the hydrolysis of mannose-containing oligosaccharides in lysosomes, preventing their pathological accumulation in cells. Regular intravenous infusions reduce mannose-rich oligosaccharide levels and improve clinical manifestations of the disease.
As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.
Yes, Velmanase Alfa is an approved drug. It has reached clinical phase 4. It is classified as a Enzyme.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4298010. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 32051. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="velmanase-alfa"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/velmanase-alfa/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/velmanase-alfa/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/velmanase-alfa/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="velmanase-alfa"></drugfyi-drug>